Adlai Nortye Ltd. (NASDAQ:ANL – Get Free Report) was the target of a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 6,800 shares, a growth of 112.5% from the December 15th total of 3,200 shares. Based on an average daily trading volume, of 16,400 shares, the short-interest ratio is presently 0.4 days.
Adlai Nortye Stock Up 1.0 %
NASDAQ:ANL opened at $2.03 on Thursday. The company has a 50-day moving average price of $2.39 and a 200-day moving average price of $2.57. Adlai Nortye has a 12 month low of $1.85 and a 12 month high of $17.48.
Analysts Set New Price Targets
Separately, HC Wainwright reiterated a “buy” rating and set a $9.00 target price on shares of Adlai Nortye in a report on Monday, November 11th.
About Adlai Nortye
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
Featured Stories
- Five stocks we like better than Adlai Nortye
- The Role Economic Reports Play in a Successful Investment Strategy
- 2 Top ETFs to Profit From the Natural Gas Price Surge
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Penny Stock BranchOut Food: Why It Won’t Stay Cheap for Long
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Bull Case for Transocean Stock: 100% Upside Could Be Within Reach
Receive News & Ratings for Adlai Nortye Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adlai Nortye and related companies with MarketBeat.com's FREE daily email newsletter.
